Eagle Victory Clears Way For US Vasopressin Launch
Endo’s Par Fails To Demonstrate Vasostrict Infringement; But CRL Must Be Overcome
Eagle Pharmaceuticals has celebrated a US court ruling that clears the way for it to launch its generic vasopressin rival to Endo’s Vasostrict. However, the company is still waiting for FDA approval after its application was delayed by a CRL earlier this year, with a new action date provided by the agency.
